Physician profile
Preetham Jetty
NPI 1962469510
$59,162.13
in general payments reported to CMS, 2019-2025
42 companies · $930 in 2025
The $930 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $13K · 2021: $15K · 2022: $9,726 · 2023: $1,404 · 2024: $1,383 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,717.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $29,544.74 | 2019-2022 | |
| Esperion Therapeutics, INC. | $23,008.31 | 2021-2023 | Nexletol |
| Pfizer INC. | $1,177.56 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $969.01 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $605.10 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $507.39 | 2019-2025 | Brilinta, Farxiga |
| Janssen Pharmaceuticals, INC | $433.89 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $332.59 | 2022-2025 | |
| Novo Nordisk INC | $245.19 | 2019-2025 | Ozempic, Wegovy |
| Amgen INC. | $231.92 | 2019-2025 | Repatha, Repatha |
| Regeneron Healthcare Solutions, INC. | $213.95 | 2019-2023 | Evkeeza |
| Boston Scientific Corporation | $199.21 | 2019-2024 | Watchman Flx, Watchman Access System |
| Eisai INC. | $191.77 | 2023-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $164.05 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $123.57 | 2022-2024 | Verquvo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $120.19 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $106.64 | 2023-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $104.55 | 2023-2024 | Inpefa |
| Kestra Medical Technology Services, INC. | $97.98 | 2024-2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $94.38 | 2019-2024 | |
| Astellas Pharma US INC | $74.46 | 2019-2022 | |
| Biotronik INC. | $72.80 | 2025 | Acticor 7 Vr-T Dx |
| Daiichi Sankyo INC. | $68.30 | 2019-2023 | Injectafer |
| Abbott Laboratories | $63.52 | 2022-2023 | Mitraclip, Confirm Rx |
| Edwards Lifesciences Corporation | $51.57 | 2025 | Sapien 3 Ultra Resilia |
| Tactile Systems Technology INC | $43.95 | 2019-2025 | Flexitouch Plus, Nimbl |
| Kowa Pharmaceuticals America, INC. | $33.91 | 2019-2021 | |
| Chiesi USA, INC. | $33.15 | 2019-2020 | |
| Scpharmaceuticals INC. | $30.32 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $25.76 | 2023 | Arcalyst |
| Gilead Sciences, INC. | $23.83 | 2019 | |
| Akcea Therapeutics, INC. | $23.06 | 2019 | |
| Alnylam Pharmaceuticals INC. | $21.96 | 2024 | Onpattro |
| Altathera Pharmaceuticals LLC | $20.44 | 2024 | Sotalol Hydrochloride |
| Amryt Pharma Holdings LTD | $20.26 | 2023 | Juxtapid |
| Celgene Corporation | $18.60 | 2019 | |
| Heartflow, INC. | $18.47 | 2025 | |
| Vifor Pharma, INC. | $16.49 | 2020 | |
| Medtronic Vascular, INC. | $15.85 | 2019 | |
| Lundbeck LLC | $13.44 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preetham Jetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.